Dallas, Texas (PRWEB) November 07, 2014
One key trend in this market is the reformulation of marketed drugs. Reformulated drugs, usually, have better tolerability and better dosing schedules than the original drugs. This increases the market acceptance of such drugs, driving their market revenue.
According to the Global Epilepsy Market 2014-2018 report" (http://www.reportsnreports.com/reports/314564-global-epilepsy-market-2014-2018.html), unmet medical needs are one of the major drivers of the market. Lack of safe, efficacious, and disease-modifying treatment is a major unmet need. Currently, drugs administered for epilepsy are intended to treat seizures. However, they fail to check the progression of the disease.
The report recognizes the following companies as the key players in the Global Epilepsy Market: GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Other Prominent Vendors in the market are: Abbvie, Eisai, F. Hoffmann-La Roche, H. Lundbeck and Janssen Pharmaceuticals.
Market Driver
Market Trend
Further, the report states that Generic erosion is one of the major challenges in the market. This, in turn, decreases the market revenue of individual drugs.
Order a copy of this report at (Prices start at US $2500 for a single user PDF) http://www.reportsnreports.com/purchase.aspx?name=314564.
List of Exhibits Exhibit 1: Market Research Methodology Exhibit 2: Global Epilepsy Market 2013-2018 (US$ million) Exhibit 3: Global Epilepsy Market Segmentation by Generation of Drugs Exhibit 4: Revenue and CAGR of Major Epilepsy Markets 2013 (US$ million) Exhibit 5: Global Epilepsy Market by Geographical Segmentation 2013 Exhibit 6: Global Epilepsy Market by Geographical Segmentation 2018 Exhibit 7: Global Epilepsy Market by Geographical Segmentation 2013-2018 (US$ million) Exhibit 8: Global Epilepsy Market by Geographical Segmentation 2013-2018 Exhibit 9: Epilepsy Market in the Americas 2013-2018 Exhibit 10: Epilepsy Market in the Americas by Geography 2013 (US$ million) Exhibit 11: Epilepsy Market in North America 2013-2018 Exhibit 12: Epilepsy Market in the US 2013-2018 Exhibit 13: Epilepsy Market in Canada 2013-2018 Exhibit 14: Epilepsy Market in EMEA by Geography 2013 Exhibit 15: Epilepsy Market in EMEA 2013-2018 Exhibit 16: Epilepsy Market in Europe 2013-2018 Exhibit 17: Epilepsy Market in APAC by Geography 2013 Exhibit 18: Revenue and CAGR of Epilepsy Market in APAC by Geography 2013 (US$ million) Exhibit 19: Epilepsy Market in APAC 2013-2018 Exhibit 20: Epilepsy Market in Japan 2013-2018 Exhibit 21: Epilepsy Market in Australia 2013-2018 Exhibit 22: Epilepsy Market in China 2013-2018 Exhibit 23: Epilepsy Market in India 2013-2018 Exhibit 24: Impact of loss of exclusivity in Canadian market for Lyrica Exhibit 25: Lyrica Revenue 2011-2013 (US$ million) Exhibit 26: Neurontin Revenue 2011-2013 (US$ million) Exhibit 27: Vimpat Revenue 2011-2013 (US$ million) Exhibit 28: Vimpat Sales by Geographical Segmentation 2013 Exhibit 29: Keppra/Keppra XR Revenue 2011-2013 (US$ million) Exhibit 30: Keppra/Keppra XR Sales by Geographical Segmentation 2013 Exhibit 31: Lamictal Revenue 2011-2013 (US$ million) Exhibit 32: Lamictal Sales by Geographical Segmentation 2013 Exhibit 33: GlaxoSmithKline: Business Segmentation 2013 Exhibit 34: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion) Exhibit 35: GlaxoSmithKline: Sales by Geography 2013 Exhibit 36: GlaxoSmithKline: Pipeline Products 2013 Exhibit 37: Pfizer: Business Segmentation by Revenue 2013 Exhibit 38: Pfizer: Business Segmentation by Revenue 2012 and 2013 Exhibit 39: Pfizer: Geographical Segmentation by Revenue 2013
View post:
Global Epilepsy Market 2014-2018 a New Research Report added to ReportsnReports.com